IL13 and asthma: It is reported that lebrikizumab, a humanized monoclonal anti-IL-13 antibody that specifically binds to IL-13 and inhibits its function, was associated with improved lung function as measured by FEV1 but did not reduce asthma exacerbations or symptoms as measured by the ACQ5 (Corren et al., 2011).